If as TD states that AMCo underachieved during the earn-out period....
"The company's net debt to estimated earnings before interest, taxes, depreciation
and amortization for 2016 is about 6.4 times, and it faces other challenges such as
potential drug price reforms in the U.K. Concordia's $3.5-billion (U.S.) acquisition of
Amdipharm Mercury in 2015 had been expected to become a primary driver of
growth, but the business underwhelmed for the nine months ended September, 2016".
"An earn-out payment of up to US$220 million may be payable to the sellers of AMCo
in 2016 should the AMCo group of companies achieve certain levels of gross profit
over a period of 12 months from October 1, 2015. This payment will not be made
should the AMCo group not achieve these targets".
JMO